T1 mapping and survival in systemic light-chain amyloidosis

Banypersad, Sanjay M.; Fontana, Marianna; Maestrini, Viviana; Sado, Daniel; Captur, Gabriella; Petrie, Aviva; Piechnik, Stefan K.; Whelan, Carol; Herrey, Anna S; Gillmore, Julian D.; Lachmann, HJ; Wechalekar, Ashutosh; Hawkins, Philip N.; Moon, James

doi:10.1093/eurheartj/ehu444

Cited by 322 publications

(226 citation statements)

References 26 publications

Supporting

Mentioning

208

Contrasting

Unclassified

Order By: Relevance

“…125 Elevated T1 on native T1 mapping (see Figure 6) has high accuracy for cardiac involvement in AL amyloidosis 126 and together with raised ECV predicts mortality. 127 Raised native T1 also has high accuracy in ATTR cardiac amyloidosis as compared with HCM, ATTR mutation carriers and normal controls, and may represent an early disease marker. 128 The value of native T1 as a marker of disease burden during therapy is under investigation in international trials of TTR-specific therapies.…”

Section: Cardiac Amyloidosismentioning

confidence: 97%

The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure

Peterzan¹,

Rider²,

Anderson³

2016

Cardiac Failure Review

View full text Add to dashboard Cite

Cardiovascular imaging is key for the assessment of patients with heart failure. Today, cardiovascular magnetic resonance imaging plays an established role in the assessment of patients with suspected and confirmed heart failure syndromes, in particular identifying aetiology. Its role in informing prognosis and guiding decisions around therapy are evolving. Key strengths include its accuracy; reproducibility; unrestricted field of view; lack of radiation; multiple abilities to characterise myocardial tissue, thrombus and scar; as well as unparalleled assessment of left and right ventricular volumes. T2* has an established role in the assessment and follow-up of iron overload cardiomyopathy and a role for T1 in specific therapies for cardiac amyloid and Anderson-Fabry disease is emerging.

show abstract

Section: Cardiac Amyloidosismentioning

confidence: 97%

The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure

Peterzan¹,

Rider²,

Anderson³

2016

Cardiac Failure Review

View full text Add to dashboard Cite

show abstract

“…T1 mapping can also provide information about disease severity and serve as a monitoring tool for chemotherapy in amyloid light-chain amyloidosis [48]. Banypersad et al [49] showed ECV was independently predictive of mortality (HR, 4.41; 95% CI: 1.35-14.4) after adjusting for E/e' , EF, diastolic dysfunction grade and NT-proBNP, but not with native T1 data in light chain amyloidosis. Greulich et al [50] reported that sarcoid patients had a higher median native T1 (994 vs. 960 ms; CVIA p<0.001), lower post-T1 (491 vs. 526 ms; p=0.001), expanded extracellular volume (28 vs. 25%; p=0.001), and higher T2 values (52 vs. 49 ms; p<0.001) compared with controls.…”

Section: Cardiac Amyloidosis and Sarcoidosismentioning

confidence: 99%

The Prognostic Role of T1 Mapping Sequences: Can T1 Mapping Parameters Have a Role in Risk Stratification?

Choi

Park

Kim

2017

Cardiovasc Imaging Asia

View full text Add to dashboard Cite

Cardiovascular disease risk stratification and prognostication are very important for treatment planning. In addition, for a growing number of patients with overt symptomatic heart failure or asymptomatic but have structural heart disease, accurate risk stratification is essential. Conventional clinical cardiovascular risk factors, several biomarkers and echo-Doppler indexes are generally used to satisfy this need. However, non-invasive approaches to direct structural and tissue characterization of the myocardium have not produced satisfactory results. The recent development of the late gadolinium enhancement (LGE) imaging allows fibrosis or myocardial inflammation to be visualized. A growing body of evidence for LGEbased prognostication has been reported. However, not all patients with heart failure or at risk for it have been assessed with LGE. Moreover, the degree of diffuse fibrosis or inflammation cannot be easily quantified with LGE techniques. Recently, introduced T1 mapping-based quantification can provide the volume of extracellular space suggestive of the degree of diffuse tissue fibrosis or inflammation. Even without gadolinium contrast, native T1 values can provide quantitative information on myocardial tissue status. Here, we review current evidence for T1 mapping-based risk stratification and prognostication for various cardiac diseases that can lead to heart failure or lethal arrhythmic events.

show abstract

“…Chen et al [69] showed that reclassification with native T1 value of ≥1015 ms using 1.5-T CMR is useful to distinguish high-risk patients for the appropriate ICD therapy or ventricular arrhythmia events in patients who received ICD implantation for primary prevention. Given the growing evidence supporting the prognostic value of T1 mapping [82,83], the use of T1 mapping might help stratify the SCD risk better by detecting subclinical myocardial changes before the emergence of systolic dysfunction and replacement fibrosis.…”

Section: Tissue Characterization Other Than Lge: T1-mappingmentioning

confidence: 99%

Evaluation of Sudden Cardiac Death Risk Using Cardiac Magnetic Resonance

Choi

Yoon

2017

Cardiovasc Imaging Asia

View full text Add to dashboard Cite

Sudden cardiac death (SCD) is not uncommon event worldwide. In a report from the Unites States, age-adjusted nationwide incidence of SCD was estimated at 60 per 100000 residents, and the public health burden of SCD is greater than individual cancer [1]. Moreover, the survival to discharge in out-of-hospital cardiac arrest is only 6.4% in patients who required emergency medical services [2]. To prevent this devastating consequence and improve survival, implantable cardioverter-defibrillator (ICD) is considered as the treatment of choice for patients who survive SCD or have a high risk of SCD. However, the decision whether to implant ICD is not straightforward. In a series of major trials, only 20−35% of patients experienced appropriate shock delivery in 1 to 3 years after ICD implantation [3]. Simultaneously, the cumulative incidence of inappropriate shock during 5 years of follow-up was 18%, which is associated with the increased risk of all-cause mortality [4]. In addition, in the pooled analysis of randomized clinical trials, 9.1% of patients experienced complications associated with ICD over 16 months [5]. Given the expense and risks of ICDs, accurately differentiating patients at higher risk of SCD is important.Based on current guidelines, ICD for primary prevention is recommended in symptomatic patients with left ventricular ejection fraction (LVEF) <35% who did not respond to medical treatment (Table 1) [6][7][8]. Therefore, to date, transthoracic echocardiography (TTE) has played a major role for identifying patients with severe left ventricular (LV) dysfunction and higher risk of SCD. However, the issue on the selection of patients for ICD implantation based on LVEF using TTE has been raised constantly [8,9]. First, although two-dimensional (2D) TTE remains the most commonly used technique for the measurement of LVEF, it is based on geometric assumptions and is often limited by the sonic window. Second, use of LVEF alone showed a lack of sensitivity and specificity for the prediction of SCD. Although patients with severe LV dysfunction were shown to be at higher risk, they constitute less than one third of SCD cases [10,11]. In many instances, SCDs occur as the first manifestation of heart disease or in patients with a heart disease but with no or mild LV systolic dysfunction [12]. In a community-based prospective study entitled Oregon Sudden Unexpected Death Study, only 20% of patients who experienced SCD were eligible for ICD implantation based on the current guidelines that included LVEF and symptoms [13].Recently, great technical advances and diminished scan times have been achieved in the field of cardiac magnetic resocc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Sudden cardiac death (SCD) is a significant problem worldwide and the risk strati...

show abstract

T1 mapping and survival in systemic light-chain amyloidosis

Cited by 322 publications

References 26 publications

The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure

The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure

The Prognostic Role of T1 Mapping Sequences: Can T1 Mapping Parameters Have a Role in Risk Stratification?

Evaluation of Sudden Cardiac Death Risk Using Cardiac Magnetic Resonance

Contact Info

Product

Resources

About